Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine

American Journal of Kidney Diseases

Volumn 33, Issue 3, 1999, Pages 555-562

  Flombaum, C D ^a   Mouradian, J A ^a   Casper, E S ^a   Erlandson, R A ^a   Benedetti, F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gemcitabine; Hemolytic uremic syndrome; Thrombotic microangiopathy

Indexed keywords

GEMCITABINE;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG SAFETY; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; LONG TERM CARE; MALE; PANCREAS CARCINOMA; SKIN BIOPSY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0033044692     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(99)70194-0     Document Type: Article

References (18)

1. B Lund PEG Kristjansen HH Hansen Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine) Cancer Treat Rev 19 1993 45 55
2. HJ Guchelaar DJ Richel A van Knapen Clinical, toxicological and pharmacological aspects of gemcitabine Cancer Treat Rev 22 1996 15 31
3. YF Hui J Reitz Gemcitabine: A cytidine analogue active against solid tumors Am J Health Syst Pharm 54 1997 162 170
4. ES Casper MR Green DP Kelsen RT Heelan TD Brown CD Flombaum B Trochanowski PG Tarassoff Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas Invest New Drugs 12 1994 29 34
5. MR Green Gemcitabine safety overview Semin Oncol 23 suppl 10 1996 S32 S35
6. Gemzar® product labeling. Indianapolis, IN, Eli Lilly and Company, March 1997
7. H Anderson B Lund F Bach N Thatcher J Walling HH Hansen Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study J Clin Oncol 12 1994 1821 1826
8. RP Abratt WR Bezwoda G Falkson L Goedhals D Hacking TA Rugg Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study J Clin Oncol 12 1994 1535 1540
9. T Brodowicz S Breiteneder C Wiltschke CC Zielinski Gemcitabine-induced hemolytic uremic syndrome: A case report J Natl Cancer Inst 89 1997 1895 1896
10. G Remuzzi A Schieppati P Ruggenenti T Bertani Thrombotic thrombocytopenia purpura, hemolytic uremic syndrome, and acute cortical necrosis ed 5 RW Schrier CW Gottschalk Diseases of the Kidney 1993 Little, Brown Boston, MA 2063 2094 chap 75
11. FG Lakkis OC Campbell KF Badr Microvascular diseases of the kidney ed 5 BM Brenner The Kidney 1996 Saunders Philadelphia, PA 1712 1730 chap 35
12. AM Jackson BD Rose LG Graff JB Jacobs JH Schwartz GM Strauss JP Yang MR Rudnick IB Elfenbein RG Narins Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy Ann Intern Med 101 1984 41 44
13. DC Fisher GB Sherrill A Hussein P Rubin JJ Vredenburgh M Elkordy W Petros WP Peters Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer Bone Marrow Transplant 18 1996 193 198
14. JE Cantrell TM Phillips PS Schein Carcinoma associated hemolytic-uremic syndrome: A complication of mitomycin-C chemotherapy J Clin Oncol 3 1985 723 734
15. HP Lohrmann W Adam B Heymer B Kubanek Microangiopathic hemolytic anemia in metastatic carcinoma: Report of eight cases Ann Intern Med 79 1973 368 375
16. GH Sack Jr J Levin WR Bell Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical pathophysiologic, and therapeutic features Medicine 56 1977 1 37
17. JB Lesesne N Rothschild B Erickson S Korec R Sisk J Keller M Arbus PV Woolley L Chiazze PS Schein JR Neefe Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry J Clin Oncol 7 1989 781 789
18. R Valavaara E Nordman Renal complications of mitomycin C therapy with special reference to total dose Cancer 55 1985 47 50